DK0946176T3 - Anvendelse af 7-(2-oxa-5,8-diazabicyclo[4.3.0]quinoloncarboxylsyre- og naphthydridoncarboxylsyrederivater til fremstilling af et lægemiddel til behandling af Helicobacter-pylori-infektioner og dermed associerede gastroduodenale sygdomme - Google Patents

Anvendelse af 7-(2-oxa-5,8-diazabicyclo[4.3.0]quinoloncarboxylsyre- og naphthydridoncarboxylsyrederivater til fremstilling af et lægemiddel til behandling af Helicobacter-pylori-infektioner og dermed associerede gastroduodenale sygdomme

Info

Publication number
DK0946176T3
DK0946176T3 DK97954354T DK97954354T DK0946176T3 DK 0946176 T3 DK0946176 T3 DK 0946176T3 DK 97954354 T DK97954354 T DK 97954354T DK 97954354 T DK97954354 T DK 97954354T DK 0946176 T3 DK0946176 T3 DK 0946176T3
Authority
DK
Denmark
Prior art keywords
carboxylic acid
oxa
diazabicyclo
helicobacter pylori
naphthydridone
Prior art date
Application number
DK97954354T
Other languages
English (en)
Inventor
Michael Matzke
Uwe Petersen
Thomas Jaetsch
Stephan Bartel
Thomas Schenke
Thomas Himmler
Bernd Baasner
Hans-Otto Werling
Klaus Schaller
Harald Labischinski
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DK0946176T3 publication Critical patent/DK0946176T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK97954354T 1996-12-16 1997-12-04 Anvendelse af 7-(2-oxa-5,8-diazabicyclo[4.3.0]quinoloncarboxylsyre- og naphthydridoncarboxylsyrederivater til fremstilling af et lægemiddel til behandling af Helicobacter-pylori-infektioner og dermed associerede gastroduodenale sygdomme DK0946176T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19652239A DE19652239A1 (de) 1996-12-16 1996-12-16 Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
PCT/EP1997/006781 WO1998026779A1 (de) 1996-12-16 1997-12-04 Verwendung von 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen

Publications (1)

Publication Number Publication Date
DK0946176T3 true DK0946176T3 (da) 2002-06-10

Family

ID=7814837

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97954354T DK0946176T3 (da) 1996-12-16 1997-12-04 Anvendelse af 7-(2-oxa-5,8-diazabicyclo[4.3.0]quinoloncarboxylsyre- og naphthydridoncarboxylsyrederivater til fremstilling af et lægemiddel til behandling af Helicobacter-pylori-infektioner og dermed associerede gastroduodenale sygdomme

Country Status (28)

Country Link
US (2) US6133260A (da)
EP (1) EP0946176B1 (da)
JP (3) JP3463939B2 (da)
KR (1) KR100536153B1 (da)
CN (1) CN100335054C (da)
AT (1) ATE214929T1 (da)
AU (1) AU717751B2 (da)
BG (1) BG64615B1 (da)
BR (1) BR9714032A (da)
CA (1) CA2274894C (da)
CZ (2) CZ297363B6 (da)
DE (2) DE19652239A1 (da)
DK (1) DK0946176T3 (da)
EA (1) EA002477B1 (da)
EE (1) EE04090B1 (da)
ES (1) ES2175519T3 (da)
HK (1) HK1025517A1 (da)
HU (1) HU226523B1 (da)
IL (1) IL130311A (da)
NO (1) NO325617B1 (da)
NZ (2) NZ336228A (da)
PL (1) PL191193B1 (da)
PT (1) PT946176E (da)
RS (1) RS49684B (da)
SK (2) SK283223B6 (da)
TR (1) TR199901754T2 (da)
UA (1) UA57055C2 (da)
WO (1) WO1998026779A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19633805A1 (de) * 1996-02-23 1997-08-28 Bayer Ag Gegenenenfalls substituierte 8-Cyan-l-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre Derivate
ATE245140T1 (de) * 1998-11-18 2003-08-15 Asahi Glass Co Ltd Derivate der aminoacryl-säure und ein verfahren zur herstellung derselben
DE19917617A1 (de) * 1999-04-19 2000-10-26 Bayer Ag -(-)Enantiomeres des 2-[2-(1-Chlor-cyclopropyl)-3-(2-chlorphenyl) 2-hydroxy-propyl]-2,4-dihydro-[1,2,4]-triazol-3-thions
NZ516201A (en) * 1999-07-01 2003-06-30 Wakunaga Pharamaceutical Co Quinolinecarboxylic acid derivative or salts thereof that have antimicrobial effect
EP1226138B1 (en) * 1999-10-08 2004-12-29 Affinium Pharmaceuticals, Inc. Fab i inhibitors
DK1560584T3 (da) * 2001-04-06 2009-05-18 Affinium Pharm Inc Fab I inhibitorer
DK1575951T3 (da) 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
ES2402420T3 (es) 2003-09-29 2013-05-03 Daiichi Sankyo Company, Limited Derivado del ácido 8-cianoquinolonacarboxílico
US7759362B2 (en) 2004-04-21 2010-07-20 Institut Of Medicinal Biotechnology Chinese Academy Of Medical Sciences Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof
CN1244582C (zh) * 2004-04-21 2006-03-08 中国医学科学院医药生物技术研究所 喹诺酮羧酸类化合物及其制备方法和医药用途
DK1828167T3 (da) * 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamidderivater som antibiotiske midler
CA2632476A1 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
JP5468899B2 (ja) 2006-07-20 2014-04-09 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉインヒビターとしてのアクリルアミド誘導体
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
ES2694775T3 (es) 2009-07-02 2018-12-27 Merlion Pharmaceuticals Pte., Ltd. Composiciones que comprenden finafloxacina y métodos de tratamiento de infecciones oftálmicas, óticas y nasales
RU2449805C1 (ru) 2011-01-27 2012-05-10 Общество С Ограниченной Ответственностью "Гармония" Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования
ES2731474T3 (es) 2012-06-19 2019-11-15 Debiopharm Int Sa Derivados de profármaco de (E)-N-metil-N-((3-metilbenzofuran-2-il)metil)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)acrilamida
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
BR112016000381A8 (pt) 2013-08-12 2020-01-07 Novartis Ag uso de um ou mais compostos antibióticos para tratamento de infecções óticas e dispositivo para uso como um kit
DE102014115951A1 (de) 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
DE102015100068A1 (de) 2015-01-06 2016-07-07 Merlion Pharmaceuticals Pte Ltd. Finafloxacin zur verwendung bei der behandlung von harnwegsinfektionen
EP3419628B1 (en) 2016-02-26 2020-10-14 Debiopharm International SA Medicament for treatment of diabetic foot infections
CN107987074B (zh) * 2017-10-27 2020-12-29 浙江美诺华药物化学有限公司 一种普拉沙星的合成方法
US11332444B2 (en) 2018-04-25 2022-05-17 Bayer Animal Health Gmbh Method for the hydrolysis of quinolonecarboxylic esters

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822801A (en) * 1984-07-20 1989-04-18 Warner-Lambert Company 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivative as antibacterial agents
JPS62205060A (ja) * 1986-03-04 1987-09-09 Kyorin Pharmaceut Co Ltd ８位置換キノロンカルボン酸誘導体
DE3702393A1 (de) * 1987-01-28 1988-08-11 Bayer Ag 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo- 3-chinolincarbonsaeuren, verfahren zu ihrer herstellung und diese enthaltende antibakterielle mittel
US5563138A (en) * 1987-04-16 1996-10-08 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US4889857A (en) * 1987-10-12 1989-12-26 Yoshitomi Pharmaceutical Industries, Ltd. Quinolonecarboxylic acid compounds and pharmaceutical use thereof
WO1989005643A1 (en) * 1987-12-18 1989-06-29 Pfizer Inc. Heterocyclic-substituted quinoline-carboxylic acids
JP2844079B2 (ja) * 1988-05-23 1999-01-06 塩野義製薬株式会社 ピリドンカルボン酸系抗菌剤
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
US5147873A (en) * 1988-08-23 1992-09-15 Pfizer Inc. Amino-substituted bridged azabicyclic quinolone carboxylic acids and esters
CA2001203C (en) * 1988-10-24 2001-02-13 Thomas P. Demuth, Jr. Novel antimicrobial dithiocarbamoyl quinolones
US5262417A (en) * 1988-12-06 1993-11-16 The Upjohn Company Antibacterial quinolone compounds
US5407932A (en) * 1989-03-31 1995-04-18 Wakunaga Seiyaku Kabushiki Kaisha Quinolone derivatives and antibacterial agents containing the same
US5252734A (en) * 1989-04-03 1993-10-12 Bayer Aktiengesellschaft Antibacterial 5-alkylquinolonecarboxylic acids
US5140033A (en) * 1989-04-03 1992-08-18 Bayer Aktiengesellschaft Antibacterial 5-alkylquinolonecarboxylic acids
DE3910663A1 (de) * 1989-04-03 1990-10-04 Bayer Ag 5-alkylchinoloncarbonsaeuren
US5164402A (en) * 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
KR910009330B1 (ko) * 1989-10-23 1991-11-11 재단법인 한국화학연구소 항균작용을 갖는 퀴놀린계 화합물과 그의 제조방법
TW209865B (da) * 1992-01-10 1993-07-21 Bayer Ag
DE4200415A1 (de) 1992-01-10 1993-07-15 Bayer Ag Enantiomerenreine 2-oxa-5,8-diazabicyclo(4.3.0)nonane sowie verfahren zu ihrer herstellung
JP3268098B2 (ja) * 1992-12-25 2002-03-25 第一製薬株式会社 二環性環状アミン誘導体
DE4309964A1 (de) 1993-03-26 1994-09-29 Bayer Ag Verfahren zur Herstellung enantiomerenreiner trans-2-Oxa-5,8-diazabicyclo[4.3.0]nonane
WO1994025464A1 (en) * 1993-04-24 1994-11-10 Korea Research Institute Of Chemical Technology Novel quinolone carboxylic acid derivatives and process for preparing the same
US5532239A (en) * 1993-08-02 1996-07-02 Assistance Publique - Hopitaux De Paris Therapeutic application of fluoroquinolone derivatives
DE4329600A1 (de) * 1993-09-02 1995-03-09 Bayer Ag Pyrido [1,2,3-d,e] [1,3,4] benzoxadiazinderivate
DK0676199T3 (da) * 1994-04-07 1999-02-08 Pfizer Anvendelse af trovafloxacin eller derivater deraf til fremstilling af et medikament til behandling af H. pylori-infektione
GB2289674A (en) * 1994-05-23 1995-11-29 Pfizer Antibacterial naphthyridine
JPH0848629A (ja) * 1994-08-08 1996-02-20 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体およびそれを有効成分とする抗ピロリ菌剤

Also Published As

Publication number Publication date
UA57055C2 (uk) 2003-06-16
JP4463380B2 (ja) 2010-05-19
NO325617B1 (no) 2008-06-30
JP2000351781A (ja) 2000-12-19
KR100536153B1 (ko) 2005-12-14
HUP0000450A3 (en) 2001-02-28
JP2009235106A (ja) 2009-10-15
US6133260A (en) 2000-10-17
CZ297363B6 (cs) 2006-11-15
PL333928A1 (en) 2000-01-31
EA002477B1 (ru) 2002-06-27
NO992903D0 (no) 1999-06-14
CA2274894A1 (en) 1998-06-25
US6432948B1 (en) 2002-08-13
CZ216899A3 (cs) 2000-02-16
JP5112395B2 (ja) 2013-01-09
CN1245428A (zh) 2000-02-23
CA2274894C (en) 2009-04-07
AU717751B2 (en) 2000-03-30
SK283224B6 (sk) 2003-03-04
HK1025517A1 (en) 2000-11-17
EE9900248A (et) 1999-12-15
JP2000514825A (ja) 2000-11-07
CZ297364B6 (cs) 2006-11-15
TR199901754T2 (xx) 1999-09-21
WO1998026779A1 (de) 1998-06-25
IL130311A (en) 2004-01-04
DE59706808D1 (de) 2002-05-02
ES2175519T3 (es) 2002-11-16
BG64615B1 (bg) 2005-09-30
KR20000069483A (ko) 2000-11-25
YU27499A (sh) 2002-10-18
HUP0000450A2 (hu) 2000-10-28
IL130311A0 (en) 2000-06-01
EP0946176A1 (de) 1999-10-06
CN100335054C (zh) 2007-09-05
NO992903L (no) 1999-06-14
SK14962000A3 (sk) 2003-01-09
DE19652239A1 (de) 1998-06-18
JP3463939B2 (ja) 2003-11-05
EA199900526A1 (ru) 2000-08-28
SK283223B6 (sk) 2003-03-04
NZ336228A (en) 2000-12-22
ATE214929T1 (de) 2002-04-15
EE04090B1 (et) 2003-08-15
BR9714032A (pt) 2000-05-09
PL191193B1 (pl) 2006-03-31
EP0946176B1 (de) 2002-03-27
AU5854198A (en) 1998-07-15
PT946176E (pt) 2002-08-30
HU226523B1 (en) 2009-03-30
BG103474A (en) 2000-01-31
RS49684B (sr) 2007-11-15
NZ506162A (en) 2001-06-29
SK79599A3 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
DK0946176T3 (da) Anvendelse af 7-(2-oxa-5,8-diazabicyclo[4.3.0]quinoloncarboxylsyre- og naphthydridoncarboxylsyrederivater til fremstilling af et lægemiddel til behandling af Helicobacter-pylori-infektioner og dermed associerede gastroduodenale sygdomme
NO20031019D0 (no) Vedvarende frigivelsesformuleringer av oksymorfon
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
NO20033181D0 (no) Substituerte alkylaminderivater og fremgangsmater for anvendelse
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
HUP0100156A2 (hu) Foszfolipáz-A2 inhibitor hatású indolszármazékok és alkalmazásuk gyógyászati készítmények előállítására
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
DE60318891D1 (de) Cyclopropylverbindungen als ccr5 antagonisten
SE9800836D0 (sv) New Compounds
DE50208008D1 (de) Tiotropiumsalze zur behandlung von entzündlichen erkrankungen
MXPA03011998A (es) Pirrolopirimidinas como inhibidores de protein cinasa.
NO976048L (no) Farmasöytiske og diett formuleringer for profylakse og behandling av mave- og tarmforstyrrelser
ATE251139T1 (de) (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten
HUP0202692A2 (hu) Interleukin-5 inhibitor hatású 6-azauracil-származékok, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik
MXPA04005809A (es) Inhibidores de proteinas quinasas.
NO20030155L (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
ATE229336T1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
ATE444762T1 (de) Therapeutische zusammenseztungen zur toleranzinduktion
DE69924105D1 (de) Iga produktionsinhibitoren
DE3575562D1 (de) Triazolopyrimidinderivate.